Our lab focuses on preclinical in vitro and in vivo studies to show how targeted radiation therapy (RT) alone or in combination with various therapeutic agents triggers an immune response. The information from these studies will pave the way for more testing this therapeutic combination in clinical trials and translational studies to benefit patients with cancer. The studies completed thus far have offered valuable insights into the role of the innate immune system in mediating tumor cell killing as a result of targeted radiation leading to sterile inflammation. Our studies have also prompted us to exploit the potential of a novel drug delivery platform to release anti-cancer agents upon activation by RT at the tumor target and its prospect to generate anti-tumor immune responses. Emerging topics such as the effect of heavy particle radiation on immune system as a mode of cancer therapy is also a major focus of studies. Future studies on these topics will help us to understand the mechanisms related to immune-mediated tumor inhibition by combined RT and immunotherapy.